

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/632,428
Confirmation No.: 4377
Filing Date: August 1, 2003
Examiner: Deepak R. Rao
Group Art Unit: 1624
Applicants: David Bebbington et al.
Title: PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE
INHIBITORS

November 10, 2008
Cambridge, Massachusetts

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is submitted in the above-identified application:

- ☒ under 37 CFR 1.97(b), and no fee is believed due because:
- ☐ The Information Disclosure Statement is being filed within three (3) months of the filing date of the application.
 - ☐ The Information Disclosure Statement is being concurrently filed with the above-identified application.
 - ☒ The Information Disclosure Statement is being concurrently filed with a Request for Continued Examination (RCE).
 - ☐ The Information Disclosure Statement is being filed prior to the mailing of a first Office Action on the merits, or
- ☐ under 37 CFR 1.97(c), after the 37 CFR 1.97(b) time period, but before the mailing date of any final action, notice of allowance or an action that otherwise closes prosecution, together with either:
- ☐ a Statement under 37 CFR 1.97(e), as checked below; or
 - ☐ a \$ 180.00 fee under 37 CFR 1.17(p), which is authorized to charge Deposit Account No. 50-0725, or

- ☐ under 37 CFR 1.97(d), after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee, together with:
- ☐ a Statement under 37 CFR 1.97(e), as checked below; and
 - ☐ a \$ 180.00 fee under 37 CFR 1.17(p), which is authorized to charge Deposit Account No. 50-0725, or
- ☐ under 37 CFR 1.97(i) after payment of issue fee: Applicant requests that the IDS and cited reference(s) be placed in the application file.

Statement under 37 CFR 1.97(e)

- ☐ Each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or
 - ☐ No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.
- ☒ Enclosed herewith is a Listing of References, PTO/SB/08a form:
- ☒ Copy of the cited Foreign Patent Document Cite No. 1 is enclosed.
 - ☐ Copies of issued U.S. patents and published U.S. applications are not required and are not being provided.
 - ☒ A copy of Office Action mailed May 22, 2008 for U.S. Application No. 10/026,992 is also enclosed.
- ☐ The “concise explanation” requirement (non-English references) for Foreign Patent Documents Cite No. 1 under 37 CFR 1.98(a)(3) is satisfied by:
- ☐ the explanation provided on the attached sheet.
 - ☐ the explanation provided in the Specification.
 - ☐ submission of the enclosed International Search Report.
 - ☐ submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.
 - ☐ the enclosed English language abstract.

- ☐ Applicant requests that the non-published pending applications listed in the attached Appendix A be considered (*Affix a label or apply the stamp "Non-Published IDS Reference-Do NOT Scan" to the front of each unpublished pending appl'n.*)
- ☐ A copy of each above-cited application, including the current claims, is enclosed, except any application filed on or after June 30, 2003, which has been scanned into the PTO's Image File Wrapper (IFW) system and is available to the examiner.
- ☐ A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. [120] [121] [365(c)] is claimed.
- ☒ The Director is hereby authorized to charge any additional fees that may be required for the Information Disclosure Statement, or credit any overpayment to Deposit Account No. 50-0725.

It is respectfully requested that the Examiner return copies of the initialed PTO/SB/08a form and when applicable the initialed Appendix A listing non-published pending application(s) indicating which references were considered with the next office communication. It is requested that the information disclosed herein be made of record in this application.

Respectfully submitted,

/H. Joon Chung/

H. Joon Chung, Reg. No. 52,748
Attorney for Applicants
c/o Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, Massachusetts 02139
Tel: (617) 444-7923
Fax: (617) 444-6483